Share This Author
Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines.
- P. Bousquet, J. Feldman, J. Schwartz
- Biology, ChemistryThe Journal of pharmacology and experimental…
- 1 July 1984
The results suggest that alpha-2 selective catecholamines are not active in the nucleus reticularis lateralis region, whereas imidazolines induce a hypotensive effect whatever their affinity for one subtype of alpha adrenoceptors.
Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.
This review focuses on the main pharmacological and clinical properties of rilmenidine and moxonidine, paying particular attention not only to their efficacy in hypertension but also to other potential cardiovascular indications.
Rilmenidine selectivity for imidazoline receptors in human brain.
Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit
- J. Feldman, E. Tibirica, G. Bricca, M. Dontenwill, A. Belcourt, P. Bousquet
- Biology, MedicineBritish journal of pharmacology
- 1 July 1990
Rilmenidine exhibited in the rabbit a central hypotensive effect which originated in the same area as where clonidine acts, and specific imidazoline‐preferring receptors appear to be involved in this hypotensiveEffect.
The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem.
Imidazoline receptors. A new concept in central regulation of the arterial blood pressure.
Rilmenidine is the first example of an hypotensive drug more selective for imidazolin preferring receptors than for classical alpha 2-adrenoceptors, and has a two to three times higher selectivity for theImidazoline receptors.
Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline-preferring receptors.
Does a second generation of centrally acting antihypertensive drugs really exist?
Central Cardiovascular Effects of a Noncatecholamine Endogenous Ligand for Clonidine Receptors
- P. Bousquet, J. Feldman, D. Atlas
- Biology, MedicineJournal of cardiovascular pharmacology
- 1 September 1986
It is concluded that CDS is an endogenous non‐catecholamine ligand for receptors involved in the hypotensive effect of clonidine and is a candidate as a neuromodulator or a neurotransmitterinvolved in the blood pressure regulation at least in the NRL region.
Respective contributions of α‐adrenergic and non‐adrenergic mechanisms in the hypotensive effect of imidazoline‐like drugs
Results indicate that an imidazoline‐like drug with no α2‐adrenergic properties lowers BP and interacts synergistically with an α2ARs agonist.